Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

B I09

🥰Excellent
Catalog No. T14847Cas No. 1607803-67-7

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

B I09

B I09

🥰Excellent
Purity: 99.64%
Catalog No. T14847Cas No. 1607803-67-7
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$44In StockIn Stock
5 mg$98In StockIn Stock
10 mg$163In StockIn Stock
25 mg$268In StockIn Stock
50 mg$396-In Stock
100 mg$562-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.64%
Contact us for more batch information

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity
Description
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
Targets&IC50
IRE1 Rnase:1230 nM
In vitro
B I09 is an IRE-1 RNase inhibitor with an IC50 of 1230 nM[1], effectively inhibiting the splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS-stimulated B cells[2]. Treatment of CLL cells with B I09 mimics XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling.
In vivo
B I09 exhibits a half-life of roughly 1.5 hours and achieves its maximum concentration of about 39 μM in mouse plasma serum within 15 minutes post-administration. Upon administration to mice bearing CLL tumors, B I09 effectively halts leukemic progression through apoptosis induction, without inducing systemic toxicity[2].
Chemical Properties
Molecular Weight303.31
FormulaC16H17NO5
Cas No.1607803-67-7
SmilesOc1ccc2c3CCNCc3c(=O)oc2c1C1OCCCO1
Relative Density.1.44 g/cm3 (Predicted)
ColorYellow
AppearanceSolid
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 11 mg/mL (36.27 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+90% Saline: 1 mg/mL (3.3 mM), Sonication is recommeded.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.2970 mL16.4848 mL32.9696 mL164.8478 mL
5 mM0.6594 mL3.2970 mL6.5939 mL32.9696 mL
10 mM0.3297 mL1.6485 mL3.2970 mL16.4848 mL
20 mM0.1648 mL0.8242 mL1.6485 mL8.2424 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

IRE-1 RNaseIRE1 RnaseB I-09B I09
Related Tags: buy B I09 | purchase B I09 | B I09 cost | order B I09 | B I09 chemical structure | B I09 in vivo | B I09 in vitro | B I09 formula | B I09 molecular weight
TargetMol | Logo

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.